Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial

Blood (2025) 146 (26): 3153–3162.

https://doi.org/10.1182/blood.2025028550

Published: 2025

Includes: Supplemental data

Journal Articles

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL

Blood (2025) 146 (20): 2406–2416.

https://doi.org/10.1182/blood.2025028899

Published: 2025

Includes: Supplemental data

Journal Articles

Redefining early vs late progressive disease (PD) in chronic lymphocytic leukemia: A pooled analysis of fixed-duration therapies

Blood (2025) 146 (Supplement 1): 2107.

https://doi.org/10.1182/blood-2025-2107

Published: 2025

Journal Articles

Characteristics and outcome of composite lymphomas: A synthetic cohort approach

Benedikt Pelzer, Sara Jennrich, Tudor-Mihai Magdas, Hans Christian Reinhardt, Bastian von Tresckow, Julia von Tresckow

Blood (2025) 146 (Supplement 1): 7098.

https://doi.org/10.1182/blood-2025-7098

Published: 2025

Journal Articles

Correlates of response to combined checkpoint and BTK inhibition for treatment of richter transformation: Extended follow-up from the prospective RT1 trial

Blood (2025) 146 (Supplement 1): 90.

https://doi.org/10.1182/blood-2025-90

Published: 2025

Journal Articles

MRD-guided venetoclax-obinutuzumab in CLL: Final analysis of the CLL2-bag trial of the gcllsg

Paula Cramer, Léa Mazot, Sandra Robrecht, Adam Giza, Anna Maria Fink, Julia Von Tresckow, Petra Langerbeins, Florian Simon, Moritz Fürstenau, Othman Al-Sawaf, Kirsten Fischer, Eugen Tausch, Ludwig Fischer von Weikersthal, Clemens-Martin Wendtner, Sebastian Böttcher, Matthias Ritgen, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek

Blood (2025) 146 (Supplement 1): 5668.

https://doi.org/10.1182/blood-2025-5668

Published: 2025

Journal Articles

Informative Censoring in Randomized First-Line Trials of Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 6799.

https://doi.org/10.1182/blood-2024-203673

Published: 2024

Journal Articles

Biallelic Deletion 13q in Chronic Lymphocytic Leukemia Treated with Targeted Agents

Malte Knöll, Rashmi Priyadharshini Dheenadayalan, Deyan Y. Yosifov, Jialei Qi, Christof Schneider, Felix Seyfried, Lueder Hinrich Meyer, Paula Cramer, Julia Von Tresckow, Michael Hallek, Barbara F. Eichhorst, Eugen Tausch, Stephan Stilgenbauer, Billy Jebaraj

Blood (2024) 144 (Supplement 1): 4608.

https://doi.org/10.1182/blood-2024-204910

Published: 2024

Journal Articles

Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial

Blood (2024) 144 (Supplement 1): 3238.

https://doi.org/10.1182/blood-2024-198917

Published: 2024

Journal Articles

Efficacy and Safety of Acalabrutinib Treatment in Very Old (≥80y) and/or Frail Patients with Chronic Lymphocytic Leukemia (CLL) - Primary Endpoint Analysis of the Phase II CLL-Frail Trial

Blood (2024) 144 (Supplement 1): 4618.

https://doi.org/10.1182/blood-2024-200848

Published: 2024

Journal Articles

Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies

Blood (2024) 143 (25): 2588–2598.

https://doi.org/10.1182/blood.2023022564

Published: 2024

Includes: Supplemental data

Journal Articles

Endpoint Surrogacy in Chronic Lymphocytic Leukemia: A Pooled Analysis of the German CLL Study Group

Blood (2023) 142 (Supplement 1): 1901.

https://doi.org/10.1182/blood-2023-178597

Published: 2023

Journal Articles

Tislelizumab Plus Zanubrutinib in Patients with Richter Transformation: Primary Endpoint Analysis of the Prospective, Multi-Center, Phase-II RT1 Trial of the German CLL Study Group

Blood (2023) 142 (Supplement 1): 204.

https://doi.org/10.1182/blood-2023-188705

Published: 2023

Journal Articles

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Blood (2023) 142 (Supplement 1): 635.

https://doi.org/10.1182/blood-2023-173709

Published: 2023

Journal Articles

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Blood (2023) 142 (Supplement 1): 4639.

https://doi.org/10.1182/blood-2023-188827

Published: 2023

Journal Articles

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/ TP53 mut

Blood (2023) 142 (11): 961–972.

https://doi.org/10.1182/blood.2023020013

Published: 2023

Includes: Supplemental data

Journal Articles

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Moritz Fürstenau, Yvonne J. Thus, Sandra Robrecht, Clemens H. M. Mellink, Anne-Marie van der Kevie-Kersemaekers, Julie Dubois, Julia von Tresckow, Michaela Patz, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar da Cunha-Bang, Christof Schneider, Christian Bjoern Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Nösslinger, Michael Baumann, Holger Hebart, Tobias Gaska, Josien C. Regelink, Ellen C. Dompeling, Vesa Lindström, Gunnar Juliusson, Anouk Widmer, Jeroen Goede, Neta Goldschmidt, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Marcel Spaargaren, Eric Eldering, Stephan Stilgenbauer, Carsten U. Niemann, Michael Hallek, Barbara Eichhorst, Karl-Anton Kreuzer, Arnon P. Kater

Blood (2023) 142 (5): 446–459.

https://doi.org/10.1182/blood.2023019634

Published: 2023

Includes: Supplemental data

Journal Articles

High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Blood (2022) 140 (Supplement 1): 842–845.

https://doi.org/10.1182/blood-2022-164786

Published: 2022

Journal Articles

Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/ TP53 Mutation

Blood (2022) 140 (Supplement 1): 834–836.

https://doi.org/10.1182/blood-2022-163245

Published: 2022

Journal Articles

Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

Blood (2022) 139 (9): 1318–1329.

https://doi.org/10.1182/blood.2021013208

Published: 2022

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL

Redefining early vs late progressive disease (PD) in chronic lymphocytic leukemia: A pooled analysis of fixed-duration therapies

Characteristics and outcome of composite lymphomas: A synthetic cohort approach

Correlates of response to combined checkpoint and BTK inhibition for treatment of richter transformation: Extended follow-up from the prospective RT1 trial

MRD-guided venetoclax-obinutuzumab in CLL: Final analysis of the CLL2-bag trial of the gcllsg

Informative Censoring in Randomized First-Line Trials of Chronic Lymphocytic Leukemia

Biallelic Deletion 13q in Chronic Lymphocytic Leukemia Treated with Targeted Agents

Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial

Efficacy and Safety of Acalabrutinib Treatment in Very Old (≥80y) and/or Frail Patients with Chronic Lymphocytic Leukemia (CLL) - Primary Endpoint Analysis of the Phase II CLL-Frail Trial

Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies

Endpoint Surrogacy in Chronic Lymphocytic Leukemia: A Pooled Analysis of the German CLL Study Group

Tislelizumab Plus Zanubrutinib in Patients with Richter Transformation: Primary Endpoint Analysis of the Prospective, Multi-Center, Phase-II RT1 Trial of the German CLL Study Group

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/ TP53 mut

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/ TP53 Mutation

Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only